A national research institute recently opened a new lab and outpost adjacent to the University of Houston's campus. Photo via UH.edu

A national organization has opened a new Houston outpost at a local university campus.

The Electrochemical Safety Research Institute, or ESRI, of UL Research Institutes opened the doors to a new laboratory in Houston in November. The new space was established to further research renewable energy technologies.

“As the world transitions from fossil fuels to sustainable energy, we are working with research teams across several organizations to lay the scientific groundwork for safe and reliable energy storage alternatives,” says Judy Jeevarajan, ESRI’s executive director, in a news release. “Since several of our research partners are based in Houston, the natural progression was to open our own laboratory in the area.”

The lab is housed in the University of Houston Technology Bridge, a startup park next to the university’s main campus. A team of ESRI’s research scientists will have access to explore the safety and performance of renewable energy technologies. Per the release, ESRI already has ongoing projects with UH within hydrogen research, solid-state batteries, and the synthesis of magnesium-ion separators.

“We are significantly expanding both our capacity and scope to better meet today’s increasingly urgent safety challenges,” says Christopher J. Cramer, ULRI’s chief research officer. “Our new Houston facility is one element of that expansion. The lab will strengthen the synergies between ESRI and our research partners in the area and accelerate scientific discoveries to help create a safer, more sustainable world.”

The facility will also act as a homebase for all Houston-area collaborations. Per the release, the new lab "will also facilitate ESRI’s research partnership with Rice University on lithium-ion cell recycling and the research institute’s work with NASA’s Johnson Space Center on thermal runaway mitigation and micro-USB lithium-ion battery safety." The organization also collaborates with Houston-based Stress Engineering Services Inc.

“We’re delighted to welcome the Electrochemical Safety Research Institute to its new home in Houston,” says Chris Taylor, executive director of the Office of Technology Transfer and Innovation at the University of Houston, in the release. “Together, we can build upon our research culture of collaboration as we pursue innovations for the greater good.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”